Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Cerulean Pharma Inc. Senior Executive to Present at the National Nanotechnology Innovation Summit: Alexandra Glucksmann Invited to Highlight Company’s Progress in Applying Nanotechnology in the Life Sciences

Abstract:
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that Alexandra Glucksmann, Ph.D., the Company's Senior Vice President, Research and Business Operations, will present at the Nanotechnology Innovation Summit being organized by the Nano Science and Technology Institute (NSTI) in celebration of the 10th anniversary of the National Nanotechnology Initiative (NNI). The Summit is being held in Washington, D.C., from December 8-10, 2010.

Cerulean Pharma Inc. Senior Executive to Present at the National Nanotechnology Innovation Summit: Alexandra Glucksmann Invited to Highlight Company’s Progress in Applying Nanotechnology in the Life Sciences

Cambridge, MA | Posted on June 3rd, 2013

Dr. Glucksmann has been invited to give an address in the Innovations in Life Science Technologies session of the Summit. In her address, she will highlight Cerulean's advancement of first-in-class nanopharmaceutical drug candidates in pre-clinical and clinical development. Additionally, Dr. Glucksmann will showcase the unique potential of Cerulean's nanopharmaceutical platform to enhance efficacy of therapeutic agents while maintaining high quality of life for patients. Dr. Glucksmann will present at 11:10 a.m. EST on Friday, December 10, 2010 in the Gaylord National Hotel and Convention Center in Washington, D.C.

The Summit is gathering leaders in nanotechnology research and development as well as in policy and finance. Other invited speakers include representatives from the White House, federal government departments and agencies, academic institutes, and industry, who will discuss the latest developments and innovations in nanotechnology. The NNI was established in 2001 with the vision of advancing leadership in nanotechnology through collaborations and dedicated funding.

####

About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of nanopharmaceuticals optimized to make drugs more effective and with fewer side effects. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Schwartz Communications
Andrew Law/Benjamin Navon
+1 781-684-0770

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanoscale view of energy storage January 16th, 2017

Seeing the quantum future... literally: What if big data could help you see the future and prevent your mobile phone from breaking before it happened? January 16th, 2017

NUS researchers achieve major breakthrough in flexible electronics: New classes of printable electrically conducting polymer materials make better electrodes for plastic electronics and advanced semiconductor devices January 14th, 2017

Manchester scientists tie the tightest knot ever achieved January 13th, 2017

Nanomedicine

New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017

Keystone Nano Announces FDA Approval Of Investigational New Drug Application For Ceramide NanoLiposome For The Improved Treatment Of Cancer January 10th, 2017

Captured on video: DNA nanotubes build a bridge between 2 molecular posts: Research may lead to new lines of direct communication with cells January 9th, 2017

Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017

Announcements

Nanoscale view of energy storage January 16th, 2017

Seeing the quantum future... literally: What if big data could help you see the future and prevent your mobile phone from breaking before it happened? January 16th, 2017

NUS researchers achieve major breakthrough in flexible electronics: New classes of printable electrically conducting polymer materials make better electrodes for plastic electronics and advanced semiconductor devices January 14th, 2017

Nanoscale Modifications can be used to Engineer Electrical Contacts for Nanodevices January 13th, 2017

Events/Classes

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Nanometrics to Present at the 19th Annual Needham Growth Conference December 22nd, 2016

Leti Will Demonstrate Fusion of Autonomous Car’s Senses: SIGMA FUSION’s Efficient, Sensor-based System Fits in a Microcontroller Platform, Anticipates Safety Requirements December 13th, 2016

Imec and Holst Centre Introduce World’s First Solid-State Multi-Ion Sensor for Internet-of-Things Applications December 13th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project